| GERON CORP. (DEL.) DL-001 |
| USA |
| Gesundheit |
| US3741631036 / 902213 |
| GON (Frankfurt) / GERN (NASDAQ) |
| FRA:GON, ETR:GON, GON:GR, NASDAQ:GERN |
| - |
| https://www.geron.com/ |
|
Geron Corporation is a commercial-stage biopharmaceutical company focused on blood cancers and myeloid hematologic malignancies through telomerase inhibition. The company's primary product is RYTELO (imetelstat), a first-in-class telomerase inhibitor..
>Volltext.. |
| 921.16 Mio. EUR |
| 829.05 Mio. EUR |
| 159.3 Mio. EUR |
| -45.6 Mio. EUR |
| -74.31 Mio. EUR |
| -0.11 EUR |
| 217.94 Mio. EUR |
| 68.82 Mio. EUR |
| -96.19 Mio. EUR |
| 3.23 |
| 110.5% |
| 56.69% |
| - |
| - |
| - |
| - |
| GERON |
| 05.04.26 |
|